Tuesday, September 23, 2014


Eventus Diagnostics, and Israeli life-sciences company, has produced a blood test for early detection of breast cancer, after 8 years of painstaking research.  Breast  cancer is by far the most common cancer in women worldwide, with 1.6MM new cases diagnosed in 2010. 

Called the Octavia Pink test, this first ever blood test to reveal cancer is available now in Israel and Italy and is undergoing clinical trials to receive US Food and Drug Administration approval.  It identifies markers that might indicate cancer or something else.  Its innovations also lie in its examination of antibodies in the blood to pinpoint this specific cancer.

The company released a peer-reviewed study that confirms the diagnostic accuracy of its Octava(TM) blood tests designed for use with screening mammography. The study showed that the Octava(TM) Blue test has excellent sensitivity and good specificity in helping to identify whether or not women who have had an abnormal mammography result actually have breast cancer. The study was conducted by researchers at Eventus Diagnostics and at major cancer centers in the U.S., Italy and Israel.

Galit Yahalom, Head of the 15-member Research Team, is a 43-year old Israeli mother of two who has worked on this project since its inception.  She says, “We know that it recognizes cancer as an external enemy that must be destroyed. It is possible that each of us has had instances of cancer we were unaware of, because our immune systems killed it when it was still very small. For whatever reason, the immune system of people with cancer is not functioning properly.” She also states, “For the last decade, we have known that there is a connection between cancer and the immune system.”

The Octava breast cancer tests are the first in a new class of rapid, accurate and cost-effective immune system-based blood tests that detect the presence or absence of cancer by measuring ratios of autoantibodies produced by the body in response to the presence of tumor-specific antigens.

Thursday, September 04, 2014